Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study
Abstract Background and Objective Mycophenolate mofetil is widely used in kidney transplant recipients. Mycophenolate mofetil is hydrolysed by blood esterases to mycophenolic acid (MPA), the active drug. Although MPA therapeutic drug monitoring has been recommended to optimise the treatment efficacy...
Guardado en:
Autores principales: | François Riglet, Julie Bertrand, Aurélie Barrail-Tran, Céline Verstuyft, Hugues Michelon, Henri Benech, Antoine Durrbach, Valérie Furlan, Caroline Barau |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Adis, Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/aebc7369cc8943ce95212329c4a83a17 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Estimation of Mycophenolic Acid Exposure in Heart Transplant Recipients by Population Pharmacokinetic and Limited Sampling Strategies
por: Xipei Wang, et al.
Publicado: (2021) -
Transplant Prognosis in Kidney Transplant Recipients with Diabetes under Mycophenolic Acid-Focused Therapeutic Drug Monitoring
por: Eisuke Nakamura, et al.
Publicado: (2021) -
Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers
por: Jae Hyun Kim, et al.
Publicado: (2018) -
Mycophenolate mofetil in the treatment of lupus nephritis
por: Patrick FK Yong, et al.
Publicado: (2008) -
Topical mycophenolate mofetil in the treatment of vitiligo: a pilot study
por: Farhad Handjani, et al.
Publicado: (2017)